H.C. Wainwright Lowers Price Target for BioXcel Therapeutics Due to Capital Structure Concerns

H.C. Wainwright has lowered its price target for BioXcel Therapeutics (BTAI) from $6 to $5, citing concerns over equity dilution. The firm maintains a Buy rating. Meanwhile, BioXcel Therapeutics has initiated a Phase 2a clinical trial for BXCL501, a drug targeting acute stress reactions.

By Laiba Immad Fri, April 17, 2026 at 4:36 PM GMT+3 2 min read · Yahoo Finance · April 17, 2026, 13:36 UTC

Tickers: $BTAI

Topics: analyst rating clinical trials equity dilution pharmaceutical research stock analysis

Read the full article at Yahoo Finance

More World news

Aline Accounting Partners Secures $206 Million in Financing Led by Square Nine Capital PR Newswire · November 12, 2026, 18:00 UTC
Egan-Jones November 2026 Report Shows Soft CLO Issuance Amid Improving Credit Metrics PR Newswire · November 12, 2026, 18:00 UTC
Blackbaud Reports Third Quarter Revenue Growth and Strategic AI Integration Motley Fool · November 12, 2026, 17:53 UTC
Sprott Physical Copper Trust Reports Significant Increase in Q3 Net Income Seeking Alpha · November 12, 2026, 17:51 UTC
Federal Reserve to Designate October 2027 Meeting as Non-Voting Strategic Session CNBC · November 12, 2026, 17:48 UTC
Sprott Physical Platinum and Palladium Trust Reports Q3 Net Income Decline Seeking Alpha · November 12, 2026, 17:47 UTC
Nvidia CEO Jensen Huang Resigns Amidst Market Volatility and AI Sector Shifts Motley Fool · November 12, 2026, 17:45 UTC
Honda to Transition CR-V Lineup to All-Hybrid Powertrains by 2027 Seeking Alpha · November 12, 2026, 17:43 UTC
Sprott Physical Silver Trust USD Reports Q3 Net Income of $425.83 Million Seeking Alpha · November 12, 2026, 17:44 UTC
Nvidia CEO Jensen Huang Resigns Amid Allegations of Personal Misconduct and China Export Control Concerns The Verge · November 12, 2026, 17:44 UTC